Back to top
more

ResMed (RMD)

(Delayed Data from NYSE)

$244.28 USD

244.28
1,118,394

+1.81 (0.75%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $244.21 -0.07 (-0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (74 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

AmerisourceBergen (ABC) Q4 Earnings & Revenues Beat Estimates

AmerisourceBergen's (ABC) Q4 earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.

Insulet (PODD) Beats on Q3 Earnings, Ups '19 Revenue View

Insulet's (PODD) year-over-year improvement in Q3 revenues on the solid uptake of Omnipod system both in the United States and across international markets looks promising.

OPKO Health (OPK) Q3 Earnings Miss Estimates, Revenues Beat

OPKO Health (OPK) third-quarter results benefit from higher Product revenues and RAYALDEE prescription growth.

CVS Health (CVS) Beats on Q3 Earnings, Raises '19 EPS Guidance

CVS Health's (CVS) strong year-over-year growth in the top line is aided by a robust performance at the Pharmacy Services segment.

Phibro's (PAHC) Q1 Earnings & Revenues Fall Y/Y, Margins Down

Phibro (PAHC) exhibits a dismal first-quarter performance on a decline in revenues at core business segments.

HMS Holdings (HMSY) Q3 Earnings Top Estimates, Revenues Miss

HMS Holdings' (HMSY) Q3 earnings benefit from higher revenues at Analytical Services unit and strong 2019 outlook.

Avanos (AVNS) Earnings and Revenues Miss Estimates in Q3

Avanos (AVNS) third-quarter results benefit from higher revenues and strong segmental performance.

NUVA vs. RMD: Which Stock Should Value Investors Buy Now?

NUVA vs. RMD: Which Stock Is the Better Value Option?

Inogen's (INGN) Q3 Earnings and Revenues Beat Estimates

Softness in domestic and international business-to-business revenues impact Inogen's (INGN) Q3 results.

STERIS' (STE) Q2 Earnings Surpass Estimates, FY20 View Up

STERIS (STE) witnesses solid revenue growth across each of its operating segments in the second quarter of fiscal 2020.

Zimmer Biomet (ZBH) Q3 Earnings Top, Operating Margin Falls

Zimmer Biomet (ZBH) gains from strong sales growth across all geographies and most operating segments in Q3.

Hill-Rom's (HRC) Q4 Earnings Beat on Strong Global Sales

Internationally, Asia Pacific, Latin America and EMEA registers strong revenue growth for Hill-Rom (HRC).

Allscripts (MDRX) Q3 Earnings Beat Estimates, Improve Y/Y

Allscripts (MDRX) third-quarter results gain from growth in bookings and solid segmental performance. Contraction in both gross and operating margins remains a woe.

Luminex (LMNX) Reports Q3 Loss, Misses Revenue Estimates

Luminex's (LMNX) Q3 earnings benefit from higher revenues and solid performance across System Sales, Consumable Sales and Service Revenues. However, gross margin contraction remains a woe.

Myriad Genetics (MYGN) Lags Q1 Earnings and Revenue Estimates

Myriad Genetics (MYGN) observes a decline in Hereditary Cancer, GeneSight, Vectra as well as Other testing revenues in Q1.

Henry Schein (HSIC) Q3 Earnings Top Estimates, Revenues Lag

Henry Schein (HSIC) registers solid performance across its key operating businesses in Q3.

Becton, Dickinson (BDX) Beats on Q4 Earnings and Revenues

Becton, Dickinson (BDX) gains from solid segmental contributions in Q4.

Tandem Diabetes (TNDM) Q3 Loss Narrows Y/Y, Sales Improve

Tandem Diabetes (TNDM) exhibits a robust performance in the third quarter of 2019, fueled by strong domestic demand.

Intersect ENT (XENT) Reports Q3 Loss, Revenues Meet Estimates

Intersect ENT (XENT) exhibits a dismal performance in the third quarter of 2019.

Haemonetics (HAE) Beats on Q2 Earnings, Raises '20 EPS View

Haemonetics (HAE) delivers robust fiscal second-quarter revenues, fueled by strong performances in Plasma and Hospital segments.

Surmodics (SRDX) Q4 Earnings and Revenues Beat Estimates

Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q4.

Bio-Rad (Bio) Q3 Earnings Beat Estimates on All-Line Growth

Growing strength in many of Bio-Rad's (Bio) key product lines across major geographic regions buoys investors' optimism on the stock.

Syneos Health (SYNH) Tops Q3 Earnings Estimates, Ups EPS View

Syneos Health (SYNH) exhibits robust topline performance in the third quarter, backed by strong segmental growth.

Integer Holdings (ITGR) Beats on Q3 Earnings, Revenues Miss

Integer Holdings' (ITGR) Q3 earnings benefit from higher revenues and strong 2019 outlook.

Bruker (BRKR) Beats Q3 Earnings Estimates, Ups EPS Guidance

Bruker (BRKR) delivers robust third-quarter revenue growth, backed by strong segmental performances.